Moderna's Total Assets for the quarter that ended in Mar. 2026 was €9,937 Mil.
During the past 12 months, Moderna's average Total Assets Growth Rate was -6.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -25.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 5.50% per year.
During the past 10 years, Moderna's highest 3-Year average Total Assets Growth Rate was 220.10%. The lowest was -25.70%. And the median was 53.20%.
Total Assets is connected with ROA %. Moderna's annualizedROA % for the quarter that ended in Mar. 2026 was -45.39%. Total Assets is also linked to Revenue through Asset Turnover. Moderna's Asset Turnover for the quarter that ended in Mar. 2026 was 0.03.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Moderna's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Moderna Total Assets Related Terms
Moderna Total Assets Historical Data
* Premium members only.
The historical data trend for Moderna's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Moderna's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (CHIX:0QFD) has a Total Assets of €9,937 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Moderna and its competitors.
Is Moderna's Total Assets too high?
Moderna's current Total Assets is €9,937 Mil. Overall, Moderna has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's Total Assets compare to RPRX and ROIV?
Moderna's Total Assets of €9,937 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Moderna and its competitors. Moderna's current Total Assets is €9,937 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.82, compared to a current price of €63.59 — trading 205.4% above its estimated fair value. The current Total Assets is €9,937 Mil. Moderna's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current Total Assets is €9,937 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (CHIX:0QFD) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of €63.59 is trading 205.4% above its estimated GF Value™ of €20.82.
GuruFocus considers Moderna to be Significantly Overvalued.
Key valuation signals for CHIX:0QFD:
Total Assets: €9,937 Mil
GF Value™: €20.82 vs. price of €63.59 (205.4% above fair value)
No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
20GF Score
Get the complete analysis for CHIX:0QFD
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:0QFD has been successfully added to your 
